MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Evaluation of Aerosolized Drugs Deposition During Mechanical Ventilation

Not Applicable
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2016-06-29
Last Posted Date
2017-02-01
Lead Sponsor
Chang Gung University
Target Recruit Count
30
Registration Number
NCT02818270
Locations
🇨🇳

Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults

Not Applicable
Completed
Conditions
Oxygen Consumption
Interventions
First Posted Date
2016-06-16
Last Posted Date
2020-10-28
Lead Sponsor
Children's Hospital Los Angeles
Target Recruit Count
24
Registration Number
NCT02802111

Secondhand Smoke Respiratory Health Study

Phase 4
Active, not recruiting
Conditions
Secondhand Smoke
Airflow Limitation
Air Trapping
Tobacco
Hyperinflation
Obstructive Lung Disease
Interventions
Drug: Albuterol
Drug: Placebo
First Posted Date
2016-06-13
Last Posted Date
2024-04-23
Lead Sponsor
University of California, San Francisco
Target Recruit Count
107
Registration Number
NCT02797275
Locations
🇺🇸

VA Medical Center, San Francisco, California, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children

Completed
Conditions
Wheeze
Food Allergy
Asthma
Obstructive Sleep Apnea
Virus
Interventions
Procedure: Bronchodilator response
Procedure: Multiple-Breath Washout
Procedure: Allergy Skin Test
Procedure: Forced Oscillation Technique
Procedure: Spirometry
Drug: salbutamol
Procedure: Nasal Brush
Procedure: Blood sample
Procedure: Basophil activation test
Procedure: Nasal swab
First Posted Date
2016-04-19
Last Posted Date
2021-02-08
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
121
Registration Number
NCT02743663
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2015-10-12
Last Posted Date
2020-07-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
63
Registration Number
NCT02573870
Locations
🇺🇸

GSK Investigational Site, McKinney, Texas, United States

Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

Not Applicable
Completed
Conditions
Asthma
Interventions
Device: Breath-Enhanced Nebulizer
Device: T-Piece Nebulizer
Drug: Albuterol
Procedure: Pre-Treatment Spirometry Measurement
Procedure: Post-Treatment Spirometry Measurement
First Posted Date
2015-10-02
Last Posted Date
2021-05-06
Lead Sponsor
Seton Healthcare Family
Target Recruit Count
118
Registration Number
NCT02566902
Locations
🇺🇸

Dell Children's Medical Center, Emergency Department, Austin, Texas, United States

Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy

Not Applicable
Completed
Conditions
Muscle Hypertrophy in Healthy Young Men
Interventions
Drug: Placebo
Drug: Salbutamol
Other: Resistance training
First Posted Date
2015-09-16
Last Posted Date
2016-03-15
Lead Sponsor
University of Copenhagen
Target Recruit Count
42
Registration Number
NCT02551276

The Effects of RPL554 on Top of Standard COPD Reliever Medications

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2015-09-04
Last Posted Date
2016-09-09
Lead Sponsor
Verona Pharma plc
Target Recruit Count
36
Registration Number
NCT02542254
Locations
🇬🇧

Medicines Evaluation Unit, Manchester, United Kingdom

Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis

Not Applicable
Completed
Conditions
Hypersensitivity Pneumonitis
Airway Disease Small
Interventions
First Posted Date
2015-08-14
Last Posted Date
2018-05-02
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
27
Registration Number
NCT02523833
Locations
🇧🇷

Olívia Meira Dias, São Paulo, Brazil

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2015-07-20
Last Posted Date
2017-11-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
60
Registration Number
NCT02502734
Locations
🇩🇰

GSK Investigational Site, Randers, Denmark

© Copyright 2025. All Rights Reserved by MedPath